目的 分析2020—2023年宜昌市中心人民醫(yī)院新型抗腫瘤藥物的使用情況和發(fā)展趨勢(shì)，為該類藥物的臨床合理使用和規(guī)范化管理提供參考。方法 收集宜昌市中心人民醫(yī)院2020年1月1日—2023年12月31日新型抗腫瘤藥物的相關(guān)用藥信息，對(duì)品種數(shù)、銷售金額、用藥頻度（DDDs）、限定日費(fèi)用（DDC）、藥品排序比（B/A）等指標(biāo)進(jìn)行回顧性統(tǒng)計(jì)分析。結(jié)果 2020—2023年新型抗腫瘤藥物的品種數(shù)呈波動(dòng)態(tài)勢(shì)，總銷售金額和總DDDs逐年增長(zhǎng)，30種藥物的DDC下降。貝伐珠單抗、奧希替尼和曲妥珠單抗的銷售金額均位居前3位。信迪利單抗的DDDs增長(zhǎng)速度最快，在2023年排名升至第1位，DDC值從2020年270.76降至2023年的102.86，連續(xù)4年B/A≥1。奧希替尼和阿美替尼的臨床使用頻率明顯增加，2023年DDDs分別排名第2、3位。伊馬替尼和吉非替尼使用頻率較高、DDC值低，B/A在4年內(nèi)均大于2，同步性好，利用度高。結(jié)論 宜昌市中心人民醫(yī)院新型抗腫瘤藥物使用量逐漸增加，藥品價(jià)格下降，符合國家政策要求及腫瘤治療的發(fā)展趨勢(shì)。

Objective To analyze the application situation and development tendency of novel antitumor drugs in Yichang Central People’s Hospital from 2020 to 2023, and to provide references for the rationally clinical application and standardized management of these drugs. Methods The drug information of novel antitumor drugs in Yichang Central People’s Hospital from January 1, 2020 to December 31, 2023 was collected, and the indexes such as variety number, consumption sum, DDDs, DDC, B/A were retrospectively analyzed. Results From 2020 to 2023, the number of novel antitumor drugs fluctuates, the total sales sum and total DDDs increase year by year, and the DDC of 30 drugs decreases. The consumption sum of bevacizumab, osimertinib, and trastuzumab ranked the top 3. The DDDs of sintilimab increased the fastest, rising to the first place in 2023, and the DDC value decreased from 270.76 in 2020 to 102.86 in 2023, with B/A≥1 for 4 consecutive years. The frequency of clinical use of osimertinib and almonertinib has increased significantly, ranking second and third respectively in DDDs in 2023. Imatinib and gefitinib had high use frequency, low DDC value, B/A greater than 2 in 4 years, good synchronization and high availability. Conclusion The usage of novel antitumor drugs in Yichang Central People’s Hospital are gradually increasing, and drug prices are decreasing, which is in line with national policy requirements and the development trend of tumor treatment.

R979.1

武漢藥學(xué)會(huì)2022年度醫(yī)院藥學(xué)學(xué)科發(fā)展孵化項(xiàng)目（WHPA2022000009）